Anyone who has a friend or relative with epilepsy may have heard about Epidiolex. In 2018, the U.S. Food and Drug Administration (FDA) approved Epidiolex (cannabidiol) to treat seizures associated with two specific forms of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. While it may sound like a typical medicine release, what made this special is that its main active ingredient is cannabidiol – the same type found in CBD oil.
With this information, you may have plenty of questions about Epidiolex and cannabidiol. Does this mean CBD oil is approved to treat certain diseases? Or will you need a prescription for your CBD oil tinctures or capsules in the future? This guide will help you understand Epidiolex and how it’s prescription medication approval by the FDA may affect you.
Epidiolex: An Oral Solution to Treat Epileptic Seizures
Epidiolex is manufactured by Greenwich Biosciences, a subsidiary of British biopharmaceutical company GW Pharmaceuticals. Interestingly, this is not the first cannabis plant derivative prescription medication made by the company. Their first was Sativex, a mouth spray intended to treat effects of multiple sclerosis.
The Carlsbad, Calif. company behind Epidiolex brands themselves as “the U.S. leader in the field of cannabinoid prescription medicines.” The claim may be well earned, as Epidiolex was the first CBD-based medication approved by the FDA for treatment of two rare yet severe forms of epilepsy.
According to the FDA, Dravet syndrome is a form of epilepsy that may appear during a child’s first year. Seizures associated with Dravet can include fever-related seizures or seizures with involuntary muscle spasms. The potential for the life-threatening status epilepticus also exists: a state of continuous seizure activity which requires emergency medical care.
While Dravet syndrome appears in the first year of a child’s life, Lennox-Gastaut syndrome first shows between ages three and five. The most common form of seizure are tonic seizures, where muscles contract uncontrollably. Associated with Lennox-Gastaut are delayed motor skills, difficulties learning and intellectual disabilities.
Prior to approval, the company performed three randomized, double-blind placebo-controlled studies to determine if Epidiolex was effective in reducing seizures. Across a total of 516 patients tested, the drug was found to reduce overall seizure frequency when taken in concert with other medications.
Does Epidiolex Make CBD Oil a Controlled Substance?
Despite the clinical trials and peer-reviewed research on cannabidiol, the question about CBD oil as a controlled substance remains a gray area. According to the Controlled Substances Act, CBD is still considered a Schedule I substance. However, several states have passed legislation either legalizing cannabis and CBD oil, or legally allow doctors to prescribe them as part of an overarching treatment plan.
That being said: the federal standard for industrial hemp is 0.3% THC, including cannabinoids. Any hemp oil products under this limit are not necessarily considered a controlled substance, making them technically legal in all 50 states. NuLeaf Naturals full spectrum CBD oil contains less than 0.3% THC, allowing you to potentially benefit from the complete range of cannabinoids without worrying about the “high” effect that comes with some cannabis use.
Is CBD Oil Approved to Treat Other Diseases?
Currently, Epidiolex is the only CBD-based treatment that is recognized by the FDA to treat any disease. Any other absolute statements about CBD oil to cure treatments have not been evaluated by the FDA. And other than Epidiolex (which is used as part of a prescribed medication regimen), CBD oil by itself is not intended for use in the diagnosis, treatment, curing, or prevention of any disease.
However, there is plenty of published peer-reviewed studies that all suggest that CBD could be beneficial as a dietary supplement. For example: a 2019 peer-reviewed case study report published by two Canadian doctors presented the use of CBD oil “for the management of chronic pain and…mood disorder” in a patient. Their continued CBD oil treatment proved effective for the patient they were working with.
“Cannabidiol use with our patient has shown promising results in controlling the pain and concomitant mood disorder,” the doctors wrote in their study. “Given our experience and the growing body of evidence for the efficacy of CBD in treating patients with multiple chronic pain conditions, it should be considered as a treatment option in the management of this patient group, especially when conventional pain medications have failed or were not well-tolerated.”
2019 continued to be a breakthrough year for CBD oil and research. Two additional studies began in the year focused around the effectiveness of cannabinoids: one lead by a Dutch team focused on phobia treatment, and the other by an international team of doctors exploring how CBD affects those with Autism Spectrum Disorders.
Will I Need to Talk to My Doctor Before Trying CBD Oil?
Although many studies suggest there may be beneficial properties to CBD oil, it’s always good to discuss any nutraceutical changes with your doctor. If you begin using CBD oil, be sure to include your doctor in the discussion, as they can guide you on dealing with changes, potential side effects, or effects on your medications.
But with the scientific discoveries, there’s no better time to consider a CBD regimen. With advances like Epidiolex on the market, potential benefits for your lifestyle could be one tincture away.
Read the original article here
Written by Joe Cortez at nuleafnaturals.com